P2RX7 and COVID-19: Regarding acute and long-term sequels of COVID-19, elevated levels of extracellular ATP induced by SARS-CoV-2 infection may trigger the hyperactivation of P2X7 receptors enhancing consequent neuroinflammatory processes, as P2X7 receptor antagonism has been proposed as a promising strategy to treat psychiatric symptoms and neurodegenerative diseases of COVID-19 patients.